



<b>Dr. Ken Tanaka, Ph.D.</b>
------------------------------

Dr. Ken Tanaka is Vice President of Research and Development at Paratek Pharmaceuticals. He has over 20 years of experience in research and development in the pharmaceutical industry at both large and small pharmaceutical companies. He received his BS degree (1974) from the University of Washington, Seattle WA, and his PhD in Microbiology (1978) from the Northwestern University, Chicago, IL. He then worked at the University of Washington, Seattle, WA as a postdoctoral fellow in Clinical Microbiology.

In 1981, he joined E.R. Squibb and Sons in 1981 where he was responsible for in vitro microbiology for the antibacterial/antifungal discovery program. He conducted in vitro MIC testing to support medicinal chemistry in the monobactam program, leading to two clinical candidate monobactams related to aztreonam. He also developed natural product screens and supported natural product discovery.

In 1987, he joined Schwarz Pharma to lead the Phase 3 development effort for a cardiovascular product for market authorization in the US.

He was Head of the Microbiology Department of Abbott Laboratories for 6 years leading the in vitro microbiology, clinical microbiology, and animal pharmacology groups. In that position he was involved in the development of clarithromycin for MAC and *H. pylori*. He was also responsible for microbiology support for clarithromycin and temafloxacin development and marketing and for microbiology and pharmacology support for medicinal chemistry projects in ketolide and pyridone antibacterials.

In 1997, Dr. Tanaka joined Pathogenesis Corporation to lead the microbiology and aerosol technology groups. He provided support for Tobi development and supported Mtb programs (rifalazil and PA-824). He was also responsible for microbiology support (in vitro and in vivo) for drug discovery effort and led the aerosol discovery effort.

Since 2001, he is Vice President of Research and Development at Paratek Pharmaceuticals in charge of medicinal chemistry, discovery biology, pharmacology, pharmacokinetics, clinical development, and regulatory affairs. He is leading Paratek's tetracycline discovery efforts for anti-infectives and anti-inflammation that have resulted in clinical development compounds, and for anti-virulence discovery effort. He is also responsible for preclinical and clinical development, with one compound in Phase 3, one in Phase 1, one in preclinical development, and two preclinical candidates, one in multiple sclerosis and the second for rheumatoid arthritis.